NCT07001358

Brief Summary

The body's systems are deeply connected, but they are often studied separately. A recent large-scale citizen-science project on women's health, called Isala, discovered a group of gut-related bacteria present in the vaginal microbiome. This finding supports the idea that gut and vaginal bacteria interact closely, a connection known as the gut-vagina axis. However, it remains unclear whether changes in gut bacteria influence the vaginal microbiome. This discovery led to an exploration of how diet affects both the gut and vaginal microbiomes. In the gut, bacteria rely on carbohydrates from food, while in the vagina, bacteria feed on glycogen, a sugar stored in the vaginal lining. This glycogen is broken down into smaller sugars, which beneficial Lactobacillus bacteria use for fermentation. Since starch is a major source of these sugars, researchers suspect that a starch-rich diet may support Lactobacillus growth, which in turn promotes vaginal health. To test this hypothesis, the Rufaida Project was launched. Ramadan is characterised by a fasting period of approximately one month during which participants abstain from eating between sunrise and sunset. Ramadan provides a unique opportunity to study how fasting affects the microbiome under controlled conditions. In this study, 50 Muslim women will be asked to provide vaginal and stool samples at eight predetermined time points-before, during, and after Ramadan. These samples will be analysed using 16S rRNA amplicon sequencing to determine bacterial composition. Comparative analysis will be conducted between samples across different time points and anatomical sites. The objective is to understand how fasting and dietary changes influence the gut and vaginal microbiomes, and whether gut bacteria play a role in shaping vaginal health. Additionally, participants will complete weekly health questionnaires. An additional study group of up to 300 Muslim women will complete weekly questionnaires without providing biological samples. This research could improve understanding of the links between diet, gut health, and vaginal health, potentially leading to new strategies for enhancing women's well-being through nutrition.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
350

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 4, 2025

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

March 25, 2025

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2025

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 3, 2025

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2026

Completed
Last Updated

June 3, 2025

Status Verified

February 1, 2025

Enrollment Period

4 months

First QC Date

March 25, 2025

Last Update Submit

May 23, 2025

Conditions

Keywords

Vaginal microbiomeGut microbiomeIntermittent fastingRamadanGut-vagina axisCitizen science

Outcome Measures

Primary Outcomes (1)

  • Characterizing the gut and vaginal microbiome in relation to dietary components and meal frequency during ramadan using 16S rRNA sequencing

    To investigate the potential influence of dietary components and meal frequency on the gut and vaginal microbiome, vaginal and stool samples will be collected from participants before, during, and after a period of intermittent fasting (Ramadan). Bacterial community composition will be determined using 16S rRNA amplicon sequencing by Illumina MiSeq analysis. Bioinformatic tools will be employed to assess taxonomic profiles across different time points and anatomical sites. Particular attention will be given to correlations between gut- and vaginal-associated microbial taxa, with the aim of identifying bacterial signatures potentially shaped by dietary changes and fasting patterns. The analysis will further explore whether specific gut microbiota are associated with the presence or modulation of vaginal microbial communities, with a focus on health-promoting taxa such as Lactobacillus species.

    up to 4 years

Secondary Outcomes (2)

  • Determining changes in psychological well-being during Ramadan through longitudinal questionnaires

    Up to 4 years

  • Characterization of metabolite profiles in vaginal and stool samples before, during, and after Ramadan fasting

    Up to 4 years

Study Arms (1)

Women participating in Ramadan

Healthy volunteers that plan on intermittent fasting during the month of Ramadan 2025. No food or drink will be consumed from sunrise until sundown

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Healthy volunteers participating in Ramadan 2025 will be recruited through various channels. The selected women can join select to join group 1 (n=50) that take biological samples and fill out weekly questionnaires, or group 2 (n=300) that fill out weekly questionnaires.

You may qualify if:

  • years or older on the moment of registration
  • Female (biological gender)
  • Currently living in Belgium
  • Sufficient knowledge of the Dutch language
  • Participating in Ramadan
  • Has signed the informed consent

You may not qualify if:

  • Breastfeeding at the start of and during the study
  • Current diagnosis of cancer and/or immunosuppressive therapy in the six months before the study
  • Cardiovascular and metabolic conditions (such as diabetes, irritable bowel syndrome, etc.)
  • Clinically significant tendency to bleed throughout history;
  • Clinically significant abnormalities of the reproductive organs;
  • Use of oral/vaginal antibiotics/antimycotics in the 2 months prior to the study;
  • Use of oral/vaginal pre-, pro-, and postbiotics (i.e., supplements in addition to diet) in the 2 weeks before and during the study;
  • Ketogenic diet in the 2 weeks before and during the study;
  • Vaginal douching during the study;
  • Concurrent participation in another clinical trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Antwerp

Antwerp, 2020, Belgium

Location

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

Vaginal swabs with human and microbial DNA Stool swabs with human and microbial DNA Stool dry samples with human and microbial DNA

MeSH Terms

Conditions

Intermittent Fasting

Condition Hierarchy (Ancestors)

FastingFeeding BehaviorBehavior

Study Officials

  • Sarah Lebeer, Professor

    Universiteit Antwerpen

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 25, 2025

First Posted

June 3, 2025

Study Start

February 4, 2025

Primary Completion

May 30, 2025

Study Completion

February 1, 2026

Last Updated

June 3, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will share

The metadata of participants in the study will be made available in a restricted access repository. * For samples and data sharing, the researchers will work with the legal department to establish Material/Data Transfer Agreements. * Sequencing data are available at the European Nucleotide Archive. * Physical samples are their origin will be stored at the decentral hub of the Antwerp biobank. * Concerning non-identifiable sample meta-data that the researchers will use in analysis and will later be published will be put available with access control via the European Genome-Phenome Archive (EGA), where data can be accessed as described upon agreeing to the harmonized Data Access Agreement (developed by the European Union standards for in silico models for personalized medicine EU-STANDS4PM, https://doi.org/10.6084/m9.figshare.23904300).

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
Following publication, the results associated with each study will also be deposited in the Dryad repository, where they will be preserved indefinitely. Sequences will be stored to ENA (public databases) and NCBI. All samples will be registered in the Biobank using the SLIMS system.
Access Criteria
A guide to data access on the EGA is available at https://ega-archive.org/access/data-access, and a data access request will be processed within 2-3 months, pending evaluation by the data access committee (existing of lab members involved in the study), and processing by the EGA.

Locations